Isis Pharmaceuticals (ISIS) 63.86 $ISIS
'Mad Money' Lightning Round: Just Say No to Conoco Stock
at The Street - Fri Feb 13, 5:00AM CST
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), CELG: 115.88 (+0.16), PEP: 99.13 (-1.14), DPS: 76.95 (-1.35), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), DATA: 99.90 (+1.40), REGN: 402.40 (+0.66)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), DPS: 76.95 (-1.35), ZTS: 45.46 (-0.33), HALO: 14.73 (+0.23), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), MRK: 58.81 (-0.07), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), REGN: 402.40 (+0.66)
Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest
at The Street - Thu Feb 12, 7:12PM CST
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
WFM: 56.15 (-0.15), MLM: 145.23 (+3.15),
72.91 (-0.81), TSLA: 203.77 (+0.89), FRPT: 16.78 (-0.12), SKX: 66.09 (-0.06), TRIP: 84.81 (+2.41), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), OWW: 11.68 (-0.04), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), WWAV: 38.65 (+0.61), DPS: 76.95 (-1.35), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), EXPE: 89.49 (-0.08), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), DATA: 99.90 (+1.40), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03)
Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Isis Pharmaceuticals announces USD5m milestone payment from Biogen Idec
M2 - Wed Feb 11, 5:08AM CST
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Tuesday that it has earned a USD5m milestone payment with respect to a neurological disorder programme partnership from Biogen Idec.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
PR Newswire - Tue Feb 10, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders. Isis will continue to evaluate the target with the goal of advancing this program into development.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
High Triglyceridemia Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Mon Feb 09, 7:32AM CST
The report "High Triglyceridemia - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for High Triglyceridemia. Triglycerides are the most ordinary form of fat in the body. Triglycerides are the main component in vegetable oils and animal fats. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/high-triglyc...eport.html.
ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
3 Biotech Stocks We've Fallen For
Motley Fool Staff - Motley Fool - Sat Feb 07, 11:09AM CST
Source: Flickr user Simon & His Camera . Love is in the air. At least it is for three of our top Motley Fool healthcare contributors. Each has a crush on a different biotech stock darling, and they all find their pick attractive for...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), CELG: 115.88 (+0.16)
'Mad Money' Lightning Round: Buy, Buy, Buy GlaxoSmithKline and Box
at The Street - Fri Feb 06, 5:00AM CST
Cramer likes JetBlue, prefers EOG Resources to Whiting Petroleum and is avoiding America Movil.
BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), AMX: 21.97 (+0.27), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), EOG: 96.92 (+2.12), IRBT: 31.16 (+0.18)
Jim Cramer's 'Mad Money' Recap: Cheap Stocks Aren't Bad Stocks
at The Street - Thu Feb 05, 7:38PM CST
Only in the stock market are lower prices seen as a bad thing, Cramer says.
MMM: 165.94 (+0.03), AMX: 21.97 (+0.27), HON: 104.38 (+0.88), NKE: 92.04 (+0.04), GMCR: 118.53 (+0.56), WMT: 85.81 (-0.08), JBLU: 16.83 (+0.09), LNKD: 269.00 (+1.83), EOG: 96.92 (+2.12), TWTR: 48.50 (+0.55), IRBT: 31.16 (+0.18), CSCO: 29.43 (-0.03), WFM: 56.15 (-0.15), BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), ETN: 72.55 (+0.90), BOX: 20.18 (+0.01), AGCO: 49.78 (+0.97), TGTX: 13.13 (-0.19), GSK: 47.94 (+1.99), IDTI: 20.56 (-0.38), HAIN: 59.48 (+0.45), UA: 73.76 (-0.19), AA: 15.81 (+0.16), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), GM: 37.62 (-0.40), DOW: 49.44 (+0.29)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
PR Newswire - Thu Feb 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx. ISIS-BIIB4Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease. ISIS-BIIB4Rx is the fourth drug to enter development as part of Isis' broad collaboration with Biogen Idec and is a distinct target and disease indication from ISIS-BIIB3Rx, which entered development in late 2014.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 7.70% Yesterday
Comtex SmarTrend(R) - Wed Feb 04, 3:50PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $57.60 to a high of $62.11. Yesterday, the shares fell 7.7%, which took the trading range below the 3-day low of $61.58 on volume of 7.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 63.86 (-0.43)
Why Isis Pharmaceuticals' Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 04, 11:26AM CST
Source: Isis Pharmaceuticals via Google Maps. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: ...
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals (ISIS) Stock Falls Today on Diabetes Drug Trial Results
at The Street - Wed Feb 04, 9:47AM CST
Shares of Isis Pharmaceuticals (ISIS) fell in morning trading Wednesday after the company changed the timetable for the results of its diabetes drug in a clinical trial.
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals (ISIS) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:46AM CST
Isis Pharmaceutical saw a big move last session, as the company’s shares fell by over nearly 6% which continued the downtrend for the company
ISIS: 63.86 (-0.43), OPHT: 51.11 (+0.12)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Wed Feb 04, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at:
ISIS: 63.86 (-0.43)
Top Performing Funds Favor Leisure, Medical, REITs
at Investor's Business Daily - Tue Feb 03, 5:22PM CST
Amid falling oil prices and Greece's possible exit from the eurozone, the stock market started the first month of the year with volatility. The best-performing mutual funds the past three months slowed their buying in January. The outlook on IBD's...
AVIV: 36.45 (-0.08), BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SPG: 193.11 (-1.61), PSA: 202.61 (-1.18), ILMN: 198.54 (+1.81), FRT: 143.96 (-0.58), JBLU: 16.83 (+0.09), EXR: 65.33 (-0.32), LUV: 43.30 (-0.20), CELG: 115.88 (+0.16), UAL: 66.23 (-1.11), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PEB: 48.98 (-0.69), REG: 66.77 (-0.46), NLS: 15.38 (+0.12)
Why Shares of Isis Pharmaceuticals, Inc. Plunged Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 11:59AM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What : Shares of Isis Pharmaceuticals dropped by nearly 10% today after...
ISIS: 63.86 (-0.43)
Isis Pharma Time Shifts Diabetes Drug Trial to Embellish Results
at The Street - Tue Feb 03, 6:59AM CST
An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
PR Newswire - Tue Feb 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1BRx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c). In patients treated with ISIS-PTP1BRx, a mean reduction in HbA1c of 0.7 percentage points from baseline was achieved at 36 weeks, compared to a mean reduction of 0.2 percentage points for placebo-treated patients (p=0.03). Patients treated with ISIS-PTP1BRx also experienced a mean reduction in body weight from baseline at 36 weeks (p=0.01). Isis plans to report the full data from this study at a medical meeting later this year.
ISIS: 63.86 (-0.43)
'Mad Money' Lightning Round: Just Say No to Conoco Stock
at The Street - Fri Feb 13, 5:00AM CST
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), CELG: 115.88 (+0.16), PEP: 99.13 (-1.14), DPS: 76.95 (-1.35), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), DATA: 99.90 (+1.40), REGN: 402.40 (+0.66)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 16.78 (-0.12), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), DPS: 76.95 (-1.35), ZTS: 45.46 (-0.33), HALO: 14.73 (+0.23), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), MRK: 58.81 (-0.07), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), REGN: 402.40 (+0.66)
Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest
at The Street - Thu Feb 12, 7:12PM CST
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
WFM: 56.15 (-0.15), MLM: 145.23 (+3.15),
72.91 (-0.81), TSLA: 203.77 (+0.89), FRPT: 16.78 (-0.12), SKX: 66.09 (-0.06), TRIP: 84.81 (+2.41), COP: 69.88 (+1.84), DIS: 104.17 (+0.59), XRX: 13.77 (+0.20), OWW: 11.68 (-0.04), PEP: 99.13 (-1.14), CELG: 115.88 (+0.16), WWAV: 38.65 (+0.61), DPS: 76.95 (-1.35), ISIS: 63.86 (-0.43), TSRA: 39.27 (-0.05), EXPE: 89.49 (-0.08), JUNO: 40.52 (+0.18), SPLK: 64.18 (+2.25), DATA: 99.90 (+1.40), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03) Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Isis Pharmaceuticals announces USD5m milestone payment from Biogen Idec
M2 - Wed Feb 11, 5:08AM CST
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Tuesday that it has earned a USD5m milestone payment with respect to a neurological disorder programme partnership from Biogen Idec.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
PR Newswire - Tue Feb 10, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders. Isis will continue to evaluate the target with the goal of advancing this program into development.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
High Triglyceridemia Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Mon Feb 09, 7:32AM CST
The report "High Triglyceridemia - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for High Triglyceridemia. Triglycerides are the most ordinary form of fat in the body. Triglycerides are the main component in vegetable oils and animal fats. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/high-triglyc...eport.html.
ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
3 Biotech Stocks We've Fallen For
Motley Fool Staff - Motley Fool - Sat Feb 07, 11:09AM CST
Source: Flickr user Simon & His Camera . Love is in the air. At least it is for three of our top Motley Fool healthcare contributors. Each has a crush on a different biotech stock darling, and they all find their pick attractive for...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), CELG: 115.88 (+0.16)
'Mad Money' Lightning Round: Buy, Buy, Buy GlaxoSmithKline and Box
at The Street - Fri Feb 06, 5:00AM CST
Cramer likes JetBlue, prefers EOG Resources to Whiting Petroleum and is avoiding America Movil.
BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), AMX: 21.97 (+0.27), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), EOG: 96.92 (+2.12), IRBT: 31.16 (+0.18)
Jim Cramer's 'Mad Money' Recap: Cheap Stocks Aren't Bad Stocks
at The Street - Thu Feb 05, 7:38PM CST
Only in the stock market are lower prices seen as a bad thing, Cramer says.
MMM: 165.94 (+0.03), AMX: 21.97 (+0.27), HON: 104.38 (+0.88), NKE: 92.04 (+0.04), GMCR: 118.53 (+0.56), WMT: 85.81 (-0.08), JBLU: 16.83 (+0.09), LNKD: 269.00 (+1.83), EOG: 96.92 (+2.12), TWTR: 48.50 (+0.55), IRBT: 31.16 (+0.18), CSCO: 29.43 (-0.03), WFM: 56.15 (-0.15), BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), ETN: 72.55 (+0.90), BOX: 20.18 (+0.01), AGCO: 49.78 (+0.97), TGTX: 13.13 (-0.19), GSK: 47.94 (+1.99), IDTI: 20.56 (-0.38), HAIN: 59.48 (+0.45), UA: 73.76 (-0.19), AA: 15.81 (+0.16), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), GM: 37.62 (-0.40), DOW: 49.44 (+0.29)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
PR Newswire - Thu Feb 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx. ISIS-BIIB4Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease. ISIS-BIIB4Rx is the fourth drug to enter development as part of Isis' broad collaboration with Biogen Idec and is a distinct target and disease indication from ISIS-BIIB3Rx, which entered development in late 2014.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 7.70% Yesterday
Comtex SmarTrend(R) - Wed Feb 04, 3:50PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $57.60 to a high of $62.11. Yesterday, the shares fell 7.7%, which took the trading range below the 3-day low of $61.58 on volume of 7.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 63.86 (-0.43)
Why Isis Pharmaceuticals' Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 04, 11:26AM CST
Source: Isis Pharmaceuticals via Google Maps. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: ...
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals (ISIS) Stock Falls Today on Diabetes Drug Trial Results
at The Street - Wed Feb 04, 9:47AM CST
Shares of Isis Pharmaceuticals (ISIS) fell in morning trading Wednesday after the company changed the timetable for the results of its diabetes drug in a clinical trial.
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals (ISIS) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:46AM CST
Isis Pharmaceutical saw a big move last session, as the company’s shares fell by over nearly 6% which continued the downtrend for the company
ISIS: 63.86 (-0.43), OPHT: 51.11 (+0.12)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Wed Feb 04, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at:
ISIS: 63.86 (-0.43)
Top Performing Funds Favor Leisure, Medical, REITs
at Investor's Business Daily - Tue Feb 03, 5:22PM CST
Amid falling oil prices and Greece's possible exit from the eurozone, the stock market started the first month of the year with volatility. The best-performing mutual funds the past three months slowed their buying in January. The outlook on IBD's...
AVIV: 36.45 (-0.08), BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SPG: 193.11 (-1.61), PSA: 202.61 (-1.18), ILMN: 198.54 (+1.81), FRT: 143.96 (-0.58), JBLU: 16.83 (+0.09), EXR: 65.33 (-0.32), LUV: 43.30 (-0.20), CELG: 115.88 (+0.16), UAL: 66.23 (-1.11), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PEB: 48.98 (-0.69), REG: 66.77 (-0.46), NLS: 15.38 (+0.12)
Why Shares of Isis Pharmaceuticals, Inc. Plunged Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 11:59AM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What : Shares of Isis Pharmaceuticals dropped by nearly 10% today after...
ISIS: 63.86 (-0.43)
Isis Pharma Time Shifts Diabetes Drug Trial to Embellish Results
at The Street - Tue Feb 03, 6:59AM CST
An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.
ISIS: 63.86 (-0.43)
Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
PR Newswire - Tue Feb 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1BRx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c). In patients treated with ISIS-PTP1BRx, a mean reduction in HbA1c of 0.7 percentage points from baseline was achieved at 36 weeks, compared to a mean reduction of 0.2 percentage points for placebo-treated patients (p=0.03). Patients treated with ISIS-PTP1BRx also experienced a mean reduction in body weight from baseline at 36 weeks (p=0.01). Isis plans to report the full data from this study at a medical meeting later this year.
ISIS: 63.86 (-0.43)
